Cellular Biomedicine Group Inc (NASDAQ:CBMG) Shorts Decreased by 8.7% After Short Covering

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Logo

Investors sentiment increased to 2 in Q1 2019. Its up 0.92, from 1.08 in 2018Q4. It is positive, as 2 investors sold Cellular Biomedicine Group, Inc. shares while 8 reduced holdings. 8 funds opened positions while 12 raised stakes. 3.15 million shares or 90.94% more from 1.65 million shares in 2018Q4 were reported.
Wells Fargo & Co Mn holds 10,451 shares. Charles Schwab Mngmt Inc holds 0% or 25,203 shares in its portfolio. Bank Of New York Mellon has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Sumitomo Mitsui Hldgs Inc holds 0.01% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 382,802 shares. Deutsche Savings Bank Ag has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bnp Paribas Arbitrage Sa stated it has 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Nikko Asset Americas accumulated 388,520 shares. Tower Capital Limited Liability (Trc) accumulated 939 shares. West Oak Capital Ltd Limited Liability Company invested in 0% or 100 shares. Platinum Management Ltd invested in 0.27% or 653,715 shares. Meeder Asset Mgmt invested in 0% or 3,229 shares. California State Teachers Retirement Sys holds 18,173 shares. Rhumbline Advisers accumulated 0% or 14,998 shares. Jpmorgan Chase And holds 0% or 2,831 shares in its portfolio. New York State Common Retirement Fund invested 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG).

The stock of Cellular Biomedicine Group Inc (NASDAQ:CBMG) registered a decrease of 8.7% in short interest. CBMG’s total short interest was 495,400 shares in August as published by FINRA. Its down 8.7% from 542,600 shares, reported previously. With 37,000 shares average volume, it will take short sellers 13 days to cover their CBMG’s short positions. The short interest to Cellular Biomedicine Group Inc’s float is 4.46%.

The stock increased 3.24% or $0.4 during the last trading session, reaching $12.76. About 48,343 shares traded or 43.20% up from the average. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has declined 34.49% since August 14, 2018 and is downtrending. It has underperformed by 34.49% the S&P500.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $245.66 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

More notable recent Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) news were published by: Seekingalpha.com which released: “Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 04, 2019, also Seekingalpha.com with their article: “Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals – Seeking Alpha” published on January 13, 2019, Finance.Yahoo.com published: “Cellular Biomedicine Group to Present at International Society for Cell and Gene Therapy Annual Meeting – Yahoo Finance” on May 29, 2019. More interesting news about Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) were released by: Seekingalpha.com and their article: “Week In Review: Yantai’s MabPlex Raises $59 Million To Expand CDMO Services – Seeking Alpha” published on January 20, 2019 as well as Seekingalpha.com‘s news article titled: “Cellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference – Slideshow – Seeking Alpha” with publication date: September 28, 2017.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.